Sumitomo Pharma (Suzhou) Co., Ltd. has been consistently committed to the academic development of central nervous diseases, actively building academic exchange platforms, and continuously promoting the development of the neuroscience field in China. In 2017, Sumitomo Pharma (Suzhou) Co., Ltd. and DXY cooperated to create a series of salon-type academic seminars named Elite’s Discourse for young and middle-aged doctors in the field of psychiatry. We created an all-around academic exchange platform under the direction of leaders in psychiatry through a series of high-quality seminars such as the Central Nervous System Summit, Anxiety Forum, Mental Journey, and SPAP.
The Sumitomo Central Nervous System Summit has been held for four successive sessions, bringing together more than 100 domestic and international well-known experts in the field of mental health, and attracting more than 10,000 medical practitioners to discuss the latest research outcomes and clinical experiences in the field of schizophrenia, which helps the development of therapeutics in neurology, promotes the progress of clinical treatment of schizophrenia and benefits more patients.
In 2021, Sumitomo Pharma (Suzhou) Co., Ltd. successfully held the Shine in the East: China-Japan Academic Exchange Event to bring the frontier overseas medical experience to China with its academic resources, building a high-level scientific exchange platform for the Chinese and Japanese medical communities. 54 experts and professors gathered together, and more than 7,200 professionals participated in the discussion to provide innovative ideas for the clinical treatment in the field of mental health, improve the life quality of patients, and promote public health.
The Sumitomo Anxiety Forum has been held for eight sessions since 2014, inviting nearly 100 renowned experts in the field of psychiatry and neurology to discuss new challenges, new needs, and new methods in the areas of anxiety, focusing on research progress in the field of anxiety, development trends in the treatment of anxiety disorders, and clinical treatment experiences of anxiety disorders and other topics. Nearly 10,000 people participated in the forum in 2021 through the online platform, contributing to the development of diagnosis and treatment of anxiety disorders and research in China.
You are about to leave the official website of Sumitomo Pharma (Suzhou) Co., Ltd. and be redirected to a third-party website. Please be aware of the risks involved.
